<DOC>
	<DOCNO>NCT00703235</DOCNO>
	<brief_summary>Diabetic macular edema common cause visual loss among diabetic patient . Studies demonstrate role vascular endothelial growth factor ( VEGF ) pathogenesis edema . This study design evaluate effect Intravitreal injection recombinant monoclonal anti-VEGF antibody , Bevacizumab , treatment diabetic macular edema .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diabetes mellitus Clinically significant macular edema Possibility perform macular OCT Consent patient inclusion study History macular photocoagulation le 6 month inclusion study Necessity surgical intervention Rejection remain study patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>